-5%
Prednisolone is a synthetic adrenocortical steroid with strong glucocorticoid activity and minimal mineralocorticoid effects.
- Mechanism: Inhibits phospholipase Aâ‚‚, reducing inflammatory mediators like leukotrienes, prostaglandins, and SRS-A.
- Absorption: Rapid and complete oral absorption.
- Protein binding: 70–90% in plasma.
- Half-life: 2–4 hours.
- Metabolism: Primarily hepatic; excreted via urine.
- Use only if benefits outweigh potential risks.
- Passes into breast milk; may affect infant growth and adrenal function.
Pednisol is prescribed for a wide range of inflammatory, autoimmune, allergic, and endocrine conditions:
- Rheumatic disorders: Psoriatic arthritis, rheumatoid arthritis (including juvenile type), ankylosing spondylitis, acute/subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis.
- Endocrine disorders: Primary/secondary adrenocortical insufficiency, congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer.
- Dermatologic diseases: Pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme, exfoliative dermatitis, mycosis fungoides, severe psoriasis.
- Allergic states: Seasonal/perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, drug hypersensitivity reactions.
- Respiratory diseases: Symptomatic sarcoidosis, berylliosis, and fulminating/aspiration pneumonitis.
- Hematologic disorders: Idiopathic thrombocytopenic purpura, secondary thrombocytopenia, autoimmune hemolytic anemia, erythroblastopenia (RBC anemia).
- Edematous states: Induction of diuresis/remission of proteinuria in nephrotic syndrome without uremia (idiopathic or lupus-related).
- Gastrointestinal diseases: Ulcerative colitis, regional enteritis.